Viking Therapeutics (VKTX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Viking Therapeutics (VKTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4.3B, trading at
Viking Therapeutics (VKTX) has a market capitalization of approximately $4.3B, trading at
Viking Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Viking Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Viking Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Viking Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 5.72x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Viking Therapeutics (VKTX) the key facts are: market cap $4.3B, 52-week range 22.959-43.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Viking Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.